Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Shilpa Medicare Ltd Stock Analysis

Small Cap
Evaluated by 2182 users | BSE: 530549 | NSE: SHILPAMED |
Pharmaceuticals & Drugs
Shilpa Medicare, established in 1987, has carved a niche for itself in the exceedingly competitive and quality-conscious sphere of pharmaceuticals manufacturing. It produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Shilpa Medicare Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation
 Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Capital Employed 14.24%12.07%17.11%11.78%14.82%10.84%7.26%6.77%9.55%5.19%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 318371571614716779789733908901916
Y-o-Y Gr. Rt.-16.7%53.9%7.4%16.7%8.8%1.2%-7%23.8%-0.8%-
Adjusted EPS (Rs.) 5.826.3611.139.3713.8912.9610.8810.7117.7310.927.66
Y-o-Y Gr. Rt.-9.3%75%-15.8%48.2%-6.7%-16.1%-1.6%65.6%-38.4%-
Book Value per Share (Rs.) 37.4743.5253.8670.9282.91123.17133.09146.89163.06181.37181.66
Adjusted Net Profit 42.846.881.972.210710488.787.31458962
Net Op. Cash Flow (Rs. Cr.) 56.743.67068.812937.544.914712447.1-
Debt to Cash Flow from Ops 1.073.011.692.740.76.444.251.323.1317.93-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Shilpa Medicare Ltd. should be analysed on a Consolidated basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 12.3%4.7%4.5%-0.8%
Adjusted EPS 7.2%-4.7%0.1%-38.4%
Book Value per Share 19.21710.911.2
Share Price 22.5% 1.1% 8.9% 4.2%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Equity (%) 17.1115.722.8415.3118.0612.788.567.6511.446.344.22
Operating Profit Margin (%) 20.1118.5421.3420.622.5420.7519.1921.0623.6319.1216.13
Net Profit Margin (%) 13.4212.6414.2311.614.6613.7211.8512.6215.799.896.82
Debt to Equity 0.220.410.30.340.140.240.180.160.290.57-
Working Capital Days 133151135158158193237266230295-
Cash Conversion Cycle 494440565984116141126165-
Loading price chart...
Corporate Governance What do we look at?
Corporate Governance
Board Credentials
Promoter's holding
Transparency
Integrity
Entity Percentage Holding
Promoters 53.25%
Institutions 18.08%
Non-Institutions 28.68%
Pledged *11.919.299.889.7710.2610.260.810.810.810.81
* Pledged shares as % of Promoter's holding (%)
Past 10 year's financial track record analysis by Moneyworks4me indicates that Shilpa Medicare Ltd is a good quality company.

Shilpa Medicare Ltd's earnings have declined by -4.7%, whereas share price has appreciated 1.1% CAGR over the past five years, indicating the company’s share price is likely overvalued. However, for specific investment actions please consult your investment advisor.

Shilpa Medicare Ltd share price has appreciated 22.8% annually (CAGR) over the past ten years.

Past 10 years financial track record analysis and assessment of future prospects by Moneyworks4me indicates that Shilpa Medicare Ltd is a good long term investment. However, you need to ensure you buy at a right price to earn good returns.

Shilpa Medicare, established in 1987, has carved a niche for itself in the exceedingly competitive and quality-conscious sphere of pharmaceuticals manufacturing. It produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.  

The company has earned its spurs as a successful and reliable partner

Shilpa Medicare, established in 1987, has carved a niche for itself in the exceedingly competitive and quality-conscious sphere of pharmaceuticals manufacturing. It produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.  

The company has earned its spurs as a successful and reliable partner within the pharmaceutical industry. Buyers within the country and from across the borders count on its fast track integrated process development and finely honed expertise of its skilled and experienced personnel. The company is already exporting to USA, Canada, Australia, Japan and European countries viz., Germany, Switzerland, Netherlands, Belgium, Spain, Greece, Cyprus, Italy, United Kingdom etc., South American countries like Mexico, Brazil, Columbia etc, African countries like Kenya, Nigeria and West Indies etc, Asian countries like Singapore, Taiwan, China, Malaysia, Thailand and closer to home to Iran, Egypt, Pakistan and Bangladesh.  Shilpa Medicare is synergizing strength through tie-ups for manufacturing products and co-marketing rights, for it believes in working together and sharing success.

Being proactive in approach, the company continually seeks out enquiry’s for development of new products drawing from the extensive knowledge-base of its qualified and experienced people as well as sophisticated facilities.

Product range of the company includes:

Oncology AP's

  • Anastrozole 
  • Bicalutamide 
  • Carboplatin 
  • Gemcitabine HCI
  •  Irinotecan HCl Trihydrate
  • Oxaliplatin 
  • Temozolomide 
  • Cisplatin 
  • 5-Fluoro
  • Bortezomib 
  • Capecitabine 
  • Decarbazine 
  • Docetaxel 
  • Gefitinib 
  • Hydroxy urea 
  • Imatinib Mesylate 
  • Lenalidomide 
  • Letrozole
  • Methotrexate 
  • Thalidomide 
  • Topotecan HCl
  • Zoledronic acid 

General APIs

  • Ambroxol HCl 
  • Ticlopidine HCl 
  • Buflomedil HCl 
  • Nifedipine 
  • Lamivudine 
  • Sildenafil Citrate 
  • Terfenadine 
  • Acebrophylline 
  • Phenylephrine HCl 
  • Ursodeoxycholic acid 

PRODUCTS UNDER DEVELOPMENT (Oncology)

  •  Bendamustine Cladribine
  •  Decitabine Disodium Pamidronate
  •  Epirubicin Exemustane
  •  Fludarabine Phosphate  Idarubicine
  •  Paclitaxel  Pemetrexed
  •  Lomustine  Methotrexate
  •  Pamidronic acid  Tandutinib 

NUTRITIONAL SUPPLEMENTS 

  • Chromium picolinate  Chromium polynicotinate   

DRUG INTERMEDIATES

  • Trans-4-amino cyclohexanol
  • 2-Amino-3,5-dibromobenzaldehyde
  • 1,3,5-Trimethoxy Benzene 
  • 1,3,5-Tribromo Benzene
  • 7-ethyl camptothecin 
  • 7-ethyl-10-hydroxy camptothecin

Awards & Achievements:

  • Karnataka State Govt. 'Best Enterpreneur Award'.
  • Govt. of India 'Best Enterpreneur Award'.
  • ‘Star Export House’ Status from Ministry of Commerce and Industry, Govt. of India
  • 'cGMP' Certificates from W.H.O. for 20 API's
  • 'Best Export Award' from Visvesvaraya Industrial Trade Centre, Bangalore, Govt. of Karnataka,  INDIA
  • 'Outstanding Industrial Award' from Indian Junior Chamber.
  • 'Registration with 'Russian Health Authority' for Ambroxol HCl
  • 'Certificate of Suitability' received from EDQM for Ambroxol HCl (R0-CEP 2004-201-Rev 00)
  • 'Certificate of Suitability' received from EDQM for Ticlopidine HCl (R0-CEP 2005-004-Rev 00)
  • 'Certificate of Suitability' received from EDQM for Carboplatin (R0-CEP 2006-212-Rev 00)
  • Patent application on Irinotecan HCl Trihydrate 'An improved process for the preparation of Irinotecan HCl Trihydrate' published as WO2006016203 on date 2006-02-16
  • Patent file for Gemcitabine HCl and Anastrozole manufacturing process.
  • Filed ASMF/EDMF of Gemcitabine HCl over 21 EU countries
  • Filed ASMF/EDMF of Irinotecan HCl Trihydrate HCl over 27 EU countries
  • Filed ASMF/EDMF of Oxaliplatin HCl over 11 EU countries
  • 'Best District Export Award' received from FKCCI, Bangalore on 16.06.2007
  • Korean FDA Approved for Gemcitabine HCl & Ambroxol HCl
  • COS received from EDQM for Buflomedil HCl (R0-CEP 2006-080-Rev.00)
  • COS received from EDQM for Oxaliplatin EP (R0-CEP 2006-201-Rev.00)
  • 'Best District Export Award' received from FKCCI, Bangalore on 20.06.2008.
  • COS received from EDQM for Gemcitabine HCl EP (R0-CEP 2006-222-Rev 00)
  • 2010 - Shilpa Medicare Limited was granted certificate of GMP Compliance of Manufacturer for Gemcitabine Hydrochloride
  • 2012 - Shilpa Medicare Ltd has been conferred First Prize of the National Energy Conservation Award-2012 in the Drugs & Pharmaceuticals Sector from Ministry of Power, New Delhi.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback